ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Mind Medicine MindMed Inc

Mind Medicine MindMed Inc (MNMD)

7.17
-0.13
(-1.78%)
7.1499
-0.0201
(-0.28%)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
7.1499
Bid
7.00
Ask
7.20
Volume
986,457
6.98 Day's Range 7.29
4.70 52 Week Range 10.4362
Market Cap
Previous Close
7.30
Open
7.06
Last Trade Time
Financial Volume
$ 7,081,515
VWAP
7.1787
Average Volume (3m)
1,176,099
Shares Outstanding
75,553,266
Dividend Yield
-
PE Ratio
-0.05
Earnings Per Share (EPS)
-1.44
Revenue
-
Net Profit
-108.68M

About Mind Medicine MindMed Inc

Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances inclu... Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies. Show more

Sector
Pharmaceutical Preparations
Industry
Unit Inv Tr, Closed-end Mgmt
Website
Headquarters
Vancouver, British Columbia, Can
Founded
2013
Mind Medicine MindMed Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MNMD. The last closing price for Mind Medicine MindMed was $7.30. Over the last year, Mind Medicine MindMed shares have traded in a share price range of $ 4.70 to $ 10.4362.

Mind Medicine MindMed currently has 75,553,266 shares outstanding. The market capitalization of Mind Medicine MindMed is $551.54 million. Mind Medicine MindMed has a price to earnings ratio (PE ratio) of -0.05.

MNMD Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.7301-9.26522842647.888.19497.149910722207.62274717CS
40.59999.158778625956.558.216.3513019037.38033523CS
120.61999.493108728946.538.214.711760996.52015228CS
260.02990.4199438202257.1210.43624.715521467.30946794CS
52-0.7001-8.918471337587.8510.43624.713383827.25553682CS
156-4.6986-39.655652614311.848519.952.1217938669.53103936CS
260-78.1506-91.617985826685.300586.552.12274253425.10965893CS

MNMD - Frequently Asked Questions (FAQ)

What is the current Mind Medicine MindMed share price?
The current share price of Mind Medicine MindMed is $ 7.1499
How many Mind Medicine MindMed shares are in issue?
Mind Medicine MindMed has 75,553,266 shares in issue
What is the market cap of Mind Medicine MindMed?
The market capitalisation of Mind Medicine MindMed is USD 551.54M
What is the 1 year trading range for Mind Medicine MindMed share price?
Mind Medicine MindMed has traded in the range of $ 4.70 to $ 10.4362 during the past year
What is the PE ratio of Mind Medicine MindMed?
The price to earnings ratio of Mind Medicine MindMed is -0.05
What is the reporting currency for Mind Medicine MindMed?
Mind Medicine MindMed reports financial results in USD
What is the latest annual profit for Mind Medicine MindMed?
The latest annual profit of Mind Medicine MindMed is USD -108.68M
What is the registered address of Mind Medicine MindMed?
The registered address for Mind Medicine MindMed is 101-1220 W 6TH AVENUE, VANCOUVER, BRITISH COLUMBIA, V6H 1A5
What is the Mind Medicine MindMed website address?
The website address for Mind Medicine MindMed is www.mindmed.com
Which industry sector does Mind Medicine MindMed operate in?
Mind Medicine MindMed operates in the UNIT INV TR, CLOSED-END MGMT sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RBNERobin Energy Ltd
$ 13.85
(313.43%)
101.81M
OPOceanPal Inc
$ 1.63
(125.45%)
80.28M
LGHLWLion Group Holding Ltd
$ 0.0052
(116.67%)
6.87M
NEONNeonode Inc
$ 16.83
(68.47%)
4.78M
ICONIcon Energy Corporation
$ 2.90
(62.01%)
59.04M
SBETSharpLink Gaming Inc
$ 9.2275
(-71.63%)
41.92M
AIHSSenmiao Technology Ltd
$ 0.381
(-63.01%)
16.8M
CHSNChanson International Holding
$ 0.22
(-60.00%)
15.15M
KWMK Wave Media Ltd
$ 2.91
(-50.43%)
2.59M
JZXNJiuzi Holdings Inc
$ 1.56
(-46.39%)
2.24M
HCTIHealthcare Triangle Inc
$ 0.0201
(-33.00%)
856.89M
GNLNGreenlane Holdings Inc
$ 0.0101
(-34.42%)
792.34M
CGBSCrown LNG Holdings Ltd
$ 0.1104
(31.43%)
788.42M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 12.655
(3.81%)
246.13M
NVDANVIDIA Corporation
$ 141.97
(-2.09%)
180.81M

MNMD Discussion

View Posts
MomsSpaghetti MomsSpaghetti 3 days ago
Ha! Just popped up on StockTwits

👍️ 1
MomsSpaghetti MomsSpaghetti 4 days ago
Nice stair stepping
👍️ 1
MomsSpaghetti MomsSpaghetti 1 week ago
Trump administration exploring potential benefits of psychedelic treatments

Fox News correspondent Alexandria Hoff discusses the Trump administration’s stances on psychedelic treatments on ‘America’s Newsroom.’

https://www.foxnews.com/video/6373914669112
👍️0
MomsSpaghetti MomsSpaghetti 1 week ago
Currently speaking at Jefferies Conference. This space is going to be like when AI hit. This is a big deal!
👍️0
MomsSpaghetti MomsSpaghetti 3 weeks ago
"In connection with her appointment as Chief Financial Officer on June 2, 2025, MindMed will grant Ms. Roberts on such date inducement awards consisting of (i) an option to purchase 500,000 common shares of the Company (the "Option") and (ii) 125,000 performance share units (the “PSUs”) (assuming achievement at target levels of performance) that, if earned, will be settled in MindMed common shares upon vesting."

That's a nice carrot to perform.

Also, Lundbeck acquired Longboard Pharmaceuticals while they were in Phase III trials also. Read that PR here... some similar parallels... they had other products, but the PR was heaviliy directed at the drug candidate in Phase 3.

Lundbeck to acquire Longboard Pharmaceuticals in a strategic deal, significantly enhancing its neuroscience pipeline - https://www.lundbeck.com/us/newsroom/2024/lundbeck-to-acquire-longboard-pharmaceuticals-in-a-strategic-deal)
👍️ 1
MomsSpaghetti MomsSpaghetti 3 weeks ago
MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

https://ir.mindmed.co/news-events/press-releases/detail/184/mindmed-strengthens-executive-team-with-appointment-of-brandi-roberts-cpa-as-chief-financial-officer
👍️ 1
MomsSpaghetti MomsSpaghetti 3 weeks ago
This is where the tide starts to shift. :)
👍️ 1
MomsSpaghetti MomsSpaghetti 3 weeks ago
Good find. Great things are coming.
👍️0
Jack Torrance Jack Torrance 3 weeks ago
Beyond excellent.
👍️ 1
MomsSpaghetti MomsSpaghetti 3 weeks ago
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors

https://www.benzinga.com/markets/cannabis/25/05/45601096/ex-govt-foe-joins-trump-rfk-jr-s-hhs-to-lead-psychedelics-policy-what-it-means-for-investors?utm_source=articleShare
👍️ 1
MomsSpaghetti MomsSpaghetti 3 weeks ago
POLITICSLawyer Who Sued Federal Health Agency Over Marijuana Rescheduling Will Now Work There, With Focus On Psychedelics

https://www.marijuanamoment.net/lawyer-who-sued-federal-health-agency-to-release-marijuana-documents-now-works-there-with-focus-on-psychedelics/

This is huge for the sector. Lock your shares. This will now officially heat up. Wow.
👍️0
Semperfiguy Semperfiguy 3 weeks ago
This article featuring Mindmed popped into my email notifications for Medscape articles I subscribe to.

https://www.medscape.com/viewarticle/lsd-anxiety-and-depression-worth-trip-2025a1000b24?ecd=mkm_ret_250524_mscpmrk_psych_depress_etid7440784&uac=129766SJ&impID=7440784
👍️ 1
MomsSpaghetti MomsSpaghetti 3 weeks ago
RBC Meeting Notes:

Synopsis of the RBC Capital Markets Interview with MindMed (MNMD), focused on key facts about the company, its clinical pipeline, regulatory progress, commercialization efforts, and R&D beyond its lead program.

Clinical Pipeline Highlights

1. MM120 – Generalized Anxiety Disorder (GAD)

Lead Candidate: MM120 (LSD D-tartrate formulation)

Indication: Generalized Anxiety Disorder (GAD)

Phase: Phase 3 (Voyage and Panorama studies)

Design & Powering:

90% power to detect a 5-point difference between 100µg dose and placebo (primary analysis).

Sample Size: 100 patients per arm, allowing for a standard deviation of 10 and a 10–15% non-evaluable rate.

Adaptive Design: Includes interim sample size re-estimation based on standard deviation and dropout rates (not on effect size) to maintain 90% power.

Extension Study:

Open-label phase with up to 4 treatments allowed.

Entry HAMD score threshold: 16 (vs. 20 for initial trial).

Double-blind period allows continued analysis of single-dose durability.

2. MM120 – Major Depressive Disorder (MDD)

Indication: Major Depressive Disorder

Phase: Phase 2b (“EMerge” study)

Operational Synergies: Shared recruitment sites with GAD trials help improve patient screening and enrollment efficiency.

Cross-eligibility Logic: Patients diagnosed with MDD but not experiencing an episode may qualify for the GAD trial, improving enrollment flexibility.

Regulatory Strategy & FDA Engagement

Breakthrough Therapy Designation: Accelerates development and review.

FDA Relationship: Positive, consistent, and collaborative for over 5 years.

Guidance Trend: No recent changes; FDA engagement has remained stable despite personnel turnover.

Regulatory Philosophy: MindMed emphasizes that while psychedelics are novel, the approach is grounded in precedents (e.g., anesthesia, interventional psychiatry) to reduce regulatory resistance.

Commercialization Strategy

U.S. Focus

Chief Commercial Officer: Matt Wiley (noted for handling complex launches).

Target Channels:

Existing interventional psychiatry clinics (4,000–5,000+ in the U.S.).

Bravado and TMS clinics are natural launch candidates.

Individual therapy offices could serve as session monitoring sites.

Infrastructure Needs

Minimal Physiological Monitoring: No need for vital signs monitoring reduces complexity.

Psychological Monitoring: Only requires supportive presence (no structured psychotherapy needed).

Reimbursement: Will leverage existing CPT/HCPCS codes; sessions billed under E/M and monitoring time codes.

Payer Strategy: Active engagement in payer education and contracting is underway.

Europe

Current Focus: Primarily on U.S. commercialization.

European Strategy: Active regulatory and development discussions ongoing to prepare for future expansion.

Market Need & Societal Support

Broad Governmental Interest: Strong bipartisan and multi-level (federal, state, local) support.

Public Health Urgency: Widespread recognition of the unmet need in anxiety and depressive disorders.

Advocacy Message: Framed to policymakers as a familiar medical approach rather than a radical new paradigm.

Early-Stage Program: R(-)-MDMA (R-MDMA)

Indication: Autism Spectrum Disorder (ASD)

Target Mechanism: Selective serotonin release (vs. dopaminergic activity in racemic MDMA)

Rationale: Enhanced prosocial behavior and emotional resonance.

Preclinical Results: Encouraging efficacy and safety profile.

Phase 1 (Single Ascending Dose): Successfully completed.

Next Step: Early Signal of Efficacy (ESE) study designed to measure improvement in:

Social behavior

Empathy

Communication
👍️ 1
MomsSpaghetti MomsSpaghetti 3 weeks ago
RBC Meeting for MindMed happening now.

https://kvgo.com/rbc/mind-medicine-inc-may-2025
👍️0
LORTAP KCOTS LORTAP KCOTS 4 weeks ago
Looking real sweet today 
👍️ 1
Jack Torrance Jack Torrance 4 weeks ago
Gearing up for the inevitable.
👍️ 1
MomsSpaghetti MomsSpaghetti 4 weeks ago
MindMed Announces New Employee Inducement Grants

This is bullish

https://www.businesswire.com/news/home/20250519674150/en
👍️ 1
MomsSpaghetti MomsSpaghetti 4 weeks ago
FDA commissioner says research on psychedelic treatment ‘top priority' | On Balance

https://www.youtube.com/watch?v=KEQFKBME668

👍️ 2
MomsSpaghetti MomsSpaghetti 1 month ago
We know this to be true.
👍️ 1
Jack Torrance Jack Torrance 1 month ago
Our time is coming.
👍️ 1
MomsSpaghetti MomsSpaghetti 1 month ago
Rising Leaders 2025: Rob Barrow On Leading MindMed’s Psychedelic Renaissance

https://insights.citeline.com/in-vivo/leadership/rising-leaders/rising-leaders-2025-rob-barrow-on-leading-mindmeds-psychedelic-renaissance-J5TLUOIOIJFUHPWMQS2PRGYPOE/
👍️ 1
MomsSpaghetti MomsSpaghetti 1 month ago
I wouldn't say that. Could have been the Form D filing, but that is not a bad thing. We're good. This is the final stretch.
👍️ 1
bubka bubka 1 month ago
Added here @ 6.81.

I must be a glutton for punishment lol
👍️0
MomsSpaghetti MomsSpaghetti 1 month ago
Institutional investors own a significant stake of 50% in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

https://finance.yahoo.com/news/institutional-investors-own-significant-stake-123730402.html
👍️ 2
bubka bubka 1 month ago
Nice catch!

https://www.11alive.com/article/news/politics/va-sec-doug-collins-says-agency-will-look-at-psychedelic-other-alternative-treatments/85-d90e6b9d-a705-4f09-aeda-5b839879bd03
👍️ 1
Semperfiguy Semperfiguy 1 month ago
Secretary of VA Collins mentioned yesterday in the 100 day cabinet meeting that evaluating psychedelic treatment for vets is a main focus. A lot of eyes were on this meeting.
👍️ 2
MomsSpaghetti MomsSpaghetti 1 month ago
Nice block acquired there.
👍️0
MomsSpaghetti MomsSpaghetti 2 months ago
Not concerned. I know we will be. This will be some of the biggest headlines when it happens.
👍️ 1
LORTAP KCOTS LORTAP KCOTS 2 months ago
We're going to be on the better side of history with this 
👍️ 2
MomsSpaghetti MomsSpaghetti 2 months ago
No, that is still very much in play.
👍️0
MomsSpaghetti MomsSpaghetti 2 months ago
This was the final stretch we've waited for. Hang tight. We have arrived. Let it steep. We are in for a strong ramp once CMSP read outs happen in June. Once that happens. Organic rise to the big wave.
👍️ 1
bubka bubka 2 months ago
Wait! A couple of more years?

So, I guess the $30-$40 billlion buyout by this June that you predicted is off the table? Imagine that! LMAO

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173524304
👍️0
pumper_stumper pumper_stumper 2 months ago
Looks like you're in for another ENZC ride here, Jack! lol How did holder yer shares work out for you there?

You've learned nothing from that, obviously!
👍️0
Jack Torrance Jack Torrance 2 months ago
It's gonna be a good next couple years. MM120 is gonna be approved, probably for both conditions. This will lead to other approvals down the road.

HOLD YER SHARES!!!
👍️0
MomsSpaghetti MomsSpaghetti 2 months ago
MindMed’s Bet on Psychedelic Psychiatry: Vanguards of Health Care

https://www.bloomberg.com/news/audio/2025-04-24/mindmed-s-bet-on-psychedelic-therapy-vanguards-of-health-care?srnd=homepage-americas
👍️ 1
MomsSpaghetti MomsSpaghetti 2 months ago
Check out this: https://www.reddit.com/r/MindMedInvestorsClub/comments/1k6g4ae/mnmd_schedule_14a_information_proxy_statement/

MNMD - SCHEDULE 14A INFORMATION - Proxy Statement Notes

Skimming through the new proxy (14A) from MindMed, I noticed something worth sharing, especially for those of us watching for long-term value or potential M&A action.

In Proposal No. 3 (page 34), which outlines the 2025 Equity Incentive Plan, there’s a line that stood out:

“A ‘liberal’ change in control definition (e.g., mergers require actual consummation) is not included.”

What this means in plain English: MindMed is using a stricter definition of “Change in Control.” Executives don’t get perks just because a deal is announced or a merger agreement is signed. They only benefit if and when the deal actually closes.

This is known as avoiding a “liberal” change in control definition. More liberal definitions let insiders cash in early — like just from a signed agreement or a change in board seats. That’s not the case here.

Instead, MindMed is requiring actual completion of a merger or acquisition before any bonuses or early stock vesting kick in. This protects investors from dilution or executive windfalls tied to deals that never even happen.

Why this matters (especially for retail investors like us):

It avoids premature executive payouts.

It shows smart governance — aligning leadership incentives with real shareholder value.

It might be a sign the company is positioning itself for possible future interest (acquisition, partnership, etc.), but doing it the right way.

To be clear — this doesn’t guarantee an M&A deal is coming. But it’s the kind of language that often appears when a company is tightening up its structure in preparation for something. Could be Phase 3 momentum, could be something bigger. Either way, the setup is solid.

Bottom line: This is investor-friendly language. And it’s refreshing to see a microcap biotech doing things by the book, instead of padding exec pay with low bars. Worth keeping an eye on.
👍️ 1
MomsSpaghetti MomsSpaghetti 2 months ago
MNMD is now considered a late Stage bio company. Hold. We are close.
👍️ 1
MomsSpaghetti MomsSpaghetti 2 months ago
All 3 Phase 3 Trials are active. Let's ride!
👍️0
MomsSpaghetti MomsSpaghetti 2 months ago
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

https://www.businesswire.com/news/home/20250414503827/en/MindMed-Announces-First-Patient-Dosed-in-Phase-3-Emerge-Study-of-MM120-in-Major-Depressive-Disorder-MDD
👍️0
MomsSpaghetti MomsSpaghetti 2 months ago
I am not a fan of what is going on. No one is really. However, there are some silver linings here.

Despite concerns around potential pharmaceutical tariffs, these recent developments might actually create significant opportunities for companies like MindMed. Rather than negatively impacting the sector, tariffs could reshape the pharmaceutical landscape in ways that positively benefit innovative, US-focused firms.

Key points highlighting the positive potential for MindMed include:

Enhanced Investment Flow: European uncertainty could redirect substantial pharma capital to the U.S., boosting investor interest and financial backing for innovative American biotech firms like MindMed.
Reduced Competition: Tariffs could discourage European competitors from quickly expanding into the U.S., giving MindMed more space and time to establish leadership in novel therapeutic areas.

Improved Industry Environment: Increased domestic pharmaceutical activity could lead to stronger industry infrastructure, talent availability, and accelerated regulatory support, benefiting MindMed’s product development and commercialization efforts.

Ultimately, rather than succumbing to tariff-related fear, uncertainty, and doubt (FUD), investors might recognize this as an opportunity for MindMed to strengthen its competitive advantage and benefit from renewed focus and investment in U.S.-based pharmaceutical innovation.
👍️ 3
Giovanni Giovanni 2 months ago
its margin calls
👍️0
bubka bubka 2 months ago
Yes, Mom, it has nothing directly to do with MNMD but it is crushing our stock price. Good luck with your catch a falling knife philosophy. This stock was struggling before Depression Don worked his magic and has only accelerated downward since.

What is happening is not good for any developmental biotech.
👍️0
MomsSpaghetti MomsSpaghetti 2 months ago
It's fear.
👍️ 1
MomsSpaghetti MomsSpaghetti 2 months ago
This has nothing to do with MindMed... f anything all this makes them more valuable. The economy is tanking due to the administration. I got a nice chuck at down on that giant dip.
👍️ 1
Giovanni Giovanni 2 months ago
people are forced to sell what is liquid
👍️0
bubka bubka 2 months ago
I don’t know about y’all but I’m getting tired of all this winning.
👍️0
Giovanni Giovanni 2 months ago

Synergistic air pollution exposure elevates depression risk: A cohort study

Depression is a leading mental health disorder worldwide, contributing substantially to the global disease burden. While emerging evidence suggests links between specific air pollutants and depression, the potential interactions among multiple pollutants remain underexplored. Here we show the influence of six common air pollutants on depressive symptoms among middle-aged and older Chinese adults. In single-pollutant models, a 10 mgm3 increase in SO2, CO, PM10, and PM2.5 is associated with increased risks of depressive symptoms, with odds ratios (95% confidence intervals) of 1.276 (1.238e1.315), 1.007 (1.006e1.008), 1.066 (1.055e1.078), and 1.130 (1.108e1.153), respectively. In two-pollutant models, SO2 remains significantly associated with depressive symptoms after adjusting for other pollutants. Multipollutant models uncover synergistic effects, with SO2, CO, NO2,PM10,andPM2.5 exhibiting significant interactions, identifying SO2 as the primary driver of these associations. Mediation analyses further indicate that cognitive and physical impairments partially mediate the relationship between air pollution and depressive symptoms. These findings underscore the critical mental health impacts of air pollution and highlight the need for integrated air quality management strategies. Targeted mitigation of specific pollutants, particularly SO2, is expected to significantly enhance public mental health outcomes. ©2024 The Authors. Published by Elsevier B.V. on behalf of Chinese Society for Environmental Sciences, Harbin Institute of Technology, Chinese Research Academy of Environmental Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
👍️0
MomsSpaghetti MomsSpaghetti 2 months ago
Trump Stalls Cannabis Reform, Plus Mindmed CEO's 2025 Outlook | Trade to BLack - Dale's Report

👍️0
MomsSpaghetti MomsSpaghetti 2 months ago
Doug Collins - United States Secretary of Veterans Affairs | SRS #187

👍️ 1
MomsSpaghetti MomsSpaghetti 2 months ago
Trump’s Veterans Secretary Had ‘Eye-Opening’ Psychedelics Talk With RFK Jr.—And He Plans To Press Congress To Act

https://www.marijuanamoment.net/trumps-veterans-secretary-had-eye-opening-psychedelics-talk-with-rfk-jr-and-he-plans-to-press-congress-to-act/
👍️ 1

Your Recent History

Delayed Upgrade Clock